Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsTSX:MDP -1.18%53 Debt-to-Equity is 0.45 as of Mar. 2026, which is 72% below its 10-year median of 1.62. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$1.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 65.35% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medexus Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
TSX:MDP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.45 Med: 1.62 Max: 3.34
Current: 0.45
During the past 13 years, the highest Debt-to-Equity Ratio of Medexus Pharmaceuticals was 3.34. The lowest was 0.45. And the median was 1.62.
TSX:MDP's Debt-to-Equity is ranked worse than 65.35% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs TSX:MDP: 0.45
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medexus Pharmaceuticals Debt-to-Equity Related Terms
Medexus Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (TSX:MDP) has a Debt-to-Equity of 0.45 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medexus Pharmaceuticals and its competitors. This is 72% below median its historical median of 1.62. Over the past decade, Medexus Pharmaceuticals' Debt-to-Equity has ranged from 0.45 to 3.34. According to the industry distribution chart, Medexus Pharmaceuticals ranks #530 out of 811 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Medexus Pharmaceuticals' Debt-to-Equity too high?
Medexus Pharmaceuticals' current Debt-to-Equity of 0.45 is 72% below median its 10-year median of 1.62. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 3.34. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Medexus Pharmaceuticals' value of 0.45 is 66.7% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #530 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #530 out of 811 companies for Debt-to-Equity. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Medexus Pharmaceuticals' value of 0.45 is 66.7% above this benchmark. Historically, Medexus Pharmaceuticals' own Debt-to-Equity has ranged from 0.45 to 3.34 over the past decade. While the company's 10-year median is 1.62 vs. the industry median of 0.27, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Debt-to-Equity of 0.45 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Debt-to-Equity is 0.45, which is 72% below median its own 10-year median of 1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.87, compared to a current price of C$5.04 — trading 169.5% above its estimated fair value. The current Debt-to-Equity is 0.45, which is 72% below median its 10-year median of 1.62 and 66.7% above the Drug Manufacturers industry median of 0.27. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Debt-to-Equity is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$5.04 is trading 169.5% above its estimated GF Value™ of C$1.87.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
Debt-to-Equity: 0.45 (72% below median its 10-year median of 1.62)
GF Value™: C$1.87 vs. price of C$5.04 (169.5% above fair value)
Industry Position: 66.7% above the Drug Manufacturers median (#530 of 811)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score
Get the complete analysis for TSX:MDP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
